- Efficacy and safety of senaparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer (FLAMES study): A randomized, double-blind, placebocontrolled, phase III trialWu, X.; Liu, J.; Wang, X.; Wang, J.; Wang, L.; Zhu, J.; Kong, B.; Fei, J.; Tang, Y.; Xia, B.; Liang, Z.; Wang, K.; Lin, Z.; Huang, Y.; Zheng, H.; Lin, A.; Jiang, K.; Wang, W.; Wang, X.; Lou, G.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- Exploratory hrd and PD-L1 analysis of l-MOCA study: Olaparib maintenance monotherapy in Asian patients with platinum-sensitive relapsed ovarian cancer.Ma, Ding; Gao, Qing-Lei; Zhu, Jianqing; Zhao, Weidong; Huang, Yi; An, Ruifang; Zheng, Hong; Qu, Pengpeng; Wang, Li; Zhou, Qi; Wang, Danbo; Lou, Ge; Wang, Jing; Low, John; Kong, Beihua; Yin, Rutie; Xie, Xing; Liu, Jihong; Sun, Wei; Zang, RongyuAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter studyLi, J.; Youguo, C.; Mian, H.; Chen, X.; Wen, H.; Kang, Y.; Liu, K. J.; Lou, G.; Wang, X.; Wen, Q. L.; Wang, L.; Lin, Z.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
会议论文
SABRINA study: A phase II study of senaparib monotherapy for patients (pts) with BRCA1/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC)
9阅读
